Physician profile
Curtis V Wolf
NPI 1386606218
$1,852.02
in general payments reported to CMS, 2019-2025
10 companies · $275 in 2025
The $275 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $18.45 · 2021: $64.91 · 2022: $61.63 · 2023: $1,125 · 2024: $140 · 2025: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $781 · Travel and Lodging: $759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $780.73 |
| Travel and Lodging | $759.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $1,064.91 | 2023 | |
| Alcon Vision LLC | $329.90 | 2019-2025 | Unity, Clareon, Acrysof Iq Panoptix Uv Iol |
| Abbvie INC. | $146.47 | 2023-2025 | Durysta |
| Sun Pharmaceutical Industries INC. | $111.84 | 2019-2023 | Xelpros, Cequa |
| Tarsus Pharmaceuticals, INC. | $60.43 | 2025 | Xdemvy |
| Glaukos Corporation | $46.45 | 2019 | |
| Bausch & Lomb Americas INC. | $34.02 | 2024-2025 | Miebo, Vyzulta, Xiidra |
| Dompe US, INC. | $26.78 | 2024 | Oxervate |
| Kala Pharmaceuticals, INC. | $15.90 | 2019 | |
| Allergan, INC. | $15.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Curtis Wolf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.